DelveInsight’s report titled “Narcolepsy Pipeline Insight 2023” offers extensive information on more than 15+ companies and over 20+ pipeline drugs in the field of Narcolepsy research. The Narcolepsy pipeline report encompasses detailed profiles of the pipeline drugs for Narcolepsy, including information on Narcolepsy clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.
For the Narcolepsy emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Narcolepsy pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Narcolepsy clinical trial studies conducted for Narcolepsy, any NDA approvals obtained for Narcolepsy, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.
To explore more information on the latest breakthroughs in the Narcolepsy Pipeline treatment landscape of the report, click here @ Narcolepsy Pipeline Outlook
Key Takeaways from the Narcolepsy Pipeline Report
- DelveInsight’s Narcolepsy Pipeline analysis depicts a robust space with 15+ active players working to develop 20+ pipeline treatment therapies.
- The leading Narcolepsy Companies are working in the market include Axsome Therapeutics, Avadel Pharmaceuticals, Suven Life Sciences, Takeda, NLS Pharmaceutics, Vallon Pharmaceuticals, Alkermes, Centessa Pharmaceuticals, Ono Pharma, Harmony Biosciences, Reset Therapeutics, XWPharma, Sunovion Pharmaceuticals, Otsuka Pharmaceutical, ConSynance Therapeutics, Alkermes, KemPharm, and others
- Promising Narcolepsy Pipeline Therapies in the various stages of development include JZP-258, Xyrem (sodium oxybate) oral solution, Modafinil, Xyrem, Armodafinil, sodium oxybate, JZP-110, and others.
- On December, 2023, Jazz Pharmaceuticals announced a drug with the name of JZP-258 by phase 4. The rationale for the interventional, open-label, single-arm design of JZP258-401 is to evaluate the clinical experience in participants with narcolepsy transitioning treatment from Xyrem to XYWAV.
- FT218 is an investigational, once-nightly formulation of sodium oxybate that includes Avadel’s MicroPump™ controlled-release (CR) technology. In December 2020, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for FT218 to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) for FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The FDA assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of October 15, 2021.
- AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the treatment of narcolepsy. It modulates noradrenergic activity to promote wakefulness, maintain muscle tone and enhance cognition. Reboxetine has an extensive safety record in Europe and in over 40 countries where it’s approved for the treatment of depression. In narcolepsy, AXS-12 is supported by positive pre-clinical and Phase 2 clinical results where it: Improved daytime sleepiness with reduced cataplexy (sudden loss of muscle control) in people with narcolepsy in an open-label pilot trial. AXS-12 has been granted U.S. Food and Drug Administration (FDA) Orphan Drug designation for the treatment of narcolepsy. The drug is currently being evaluated in Phase III stage of development.
Narcolepsy Overview
Narcolepsy is a rare long-term brain condition that causes a person to suddenly fall asleep at inappropriate times. The brain is unable to regulate sleeping and waking patterns normally, which can result in: excessive daytime sleepiness – feeling very drowsy throughout the day and finding it difficult to concentrate and stay awake, sleep attacks – falling asleep suddenly and without warning, cataplexy – temporary loss of muscle control resulting in weakness and possible collapse, often in response to emotions such as laughter and anger, sleep paralysis – a temporary inability to move or speak when waking up or falling asleep, excessive dreaming and waking in the night – dreams often come as you fall asleep (hypnogogic hallucinations) or just before or during waking (hypnopompic hallucinations).
For further information, refer to the detailed Narcolepsy Unmet Needs, Narcolepsy Market Drivers, and Market Barriers, click here for Narcolepsy Ongoing Clinical Trial Analysis
Narcolepsy Emerging Drugs Profile
- FT218: Avadel Pharmaceuticals
- AXS-12: Axsome therapeutics
Narcolepsy Pipeline Therapeutics Assessment
There are approx. 15+ Narcolepsy companies which are developing the therapies for Narcolepsy. The Narcolepsy companies which have their Narcolepsy drug candidates in the most advanced stage, i.e. Preregistration include, Avadel Pharmaceuticals.
Request a sample and discover the recent advances in Narcolepsy Ongoing Clinical Trial Analysis and Medications, click here @ Narcolepsy Treatment Landscape
Narcolepsy Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Narcolepsy Therapeutics Market include-
Axsome Therapeutics, Avadel Pharmaceuticals, Suven Life Sciences, Takeda, NLS Pharmaceutics, Vallon Pharmaceuticals, Alkermes, Centessa Pharmaceuticals, Ono Pharma, Harmony Biosciences, Reset Therapeutics, XWPharma, Sunovion Pharmaceuticals, Otsuka Pharmaceutical, ConSynance Therapeutics, Alkermes, KemPharm, and others.
Dive deep into rich insights for drugs for Narcolepsy Pipeline, click here @ Narcolepsy Unmet Needs and Analyst Views
Scope of the Narcolepsy Pipeline Report
- Coverage- Global
- Narcolepsy Companies- Axsome Therapeutics, Avadel Pharmaceuticals, Suven Life Sciences, Takeda, NLS Pharmaceutics, Vallon Pharmaceuticals, Alkermes, Centessa Pharmaceuticals, Ono Pharma, Harmony Biosciences, Reset Therapeutics, XWPharma, Sunovion Pharmaceuticals, Otsuka Pharmaceutical, ConSynance Therapeutics, Alkermes, KemPharm, and others.
- Narcolepsy Therapies- JZP-258, Xyrem (sodium oxybate) oral solution, Modafinil, Xyrem, Armodafinil, sodium oxybate, JZP-110, and others.
- Narcolepsy Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Narcolepsy Mergers and acquisitions, Narcolepsy Licensing Activities @ Narcolepsy Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Narcolepsy Executive Summary
- Narcolepsy: Overview
- Narcolepsy Pipeline Therapeutics
- Narcolepsy Therapeutic Assessment
- Late Stage Products (Preregistration)
- FT218: Avadel Pharmaceuticals
- Drug profiles in the detailed report…..
- Late Stage Products (Phase III)
- AXS-12: Axsome therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TAK-994: Takeda
- Drug profiles in the detailed report…..
- Early stage products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Narcolepsy Key Companies
- Narcolepsy Key Products
- Narcolepsy- Unmet Needs
- Narcolepsy- Market Drivers and Barriers
- Narcolepsy- Future Perspectives and Conclusion
- Narcolepsy Analyst Views
- Narcolepsy Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/out-licensing-opportunity